Synonym
xanthone III; xanthoneIII; xanthone-III; Jacareubin
IUPAC/Chemical Name
5,9,10-trihydroxy-2,2-dimethyl-2H,6H-pyrano[3,2-b]xanthen-6-one
InChi Key
UCLUVPCGXYTYEK-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H14O6/c1-18(2)6-5-8-11(24-18)7-12-13(14(8)20)15(21)9-3-4-10(19)16(22)17(9)23-12/h3-7,19-20,22H,1-2H3
SMILES Code
CC1(C)C=CC2=C(C=C3C(C(C4=C(C(O)=C(O)C=C4)O3)=O)=C2O)O1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
In 1939, xanthone was introduced as an insecticide and it currently finds uses as ovicide for codling moth eggs and as a larvicide. Xanthone is also used in the preparation of xanthydrol, which is used in the determination of urea levels in the blood. It can also be used as a photocatalyst.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
326.30
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Khoobchandani M, Katti KK, Karikachery AR, Thipe VC, Srisrimal D, Dhurvas Mohandoss DK, Darshakumar RD, Joshi CM, Katti KV. New Approaches in Breast Cancer Therapy Through Green Nanotechnology and Nano-Ayurvedic Medicine - Pre- Clinical and Pilot Human Clinical Investigations. Int J Nanomedicine. 2020 Jan 13;15:181-197. doi: 10.2147/IJN.S219042. PMID: 32021173; PMCID: PMC6970107.
2: Tsujimoto T, Nishihara M, Osumi Y, Hakamatsuka T, Goda Y, Uchiyama N, Ozeki Y. Structural Analysis of Polygalaxanthones, C-Glucosyl Xanthones of Polygala tenuifolia Roots. Chem Pharm Bull (Tokyo). 2019;67(11):1242-1247. doi: 10.1248/cpb.c19-00608. PMID: 31685751.
3: Li L, Liu M, Cao M, He T, Bai X. Research progress on SIRT1 and sepsis. Histol Histopathol. 2019 Nov;34(11):1205-1215. doi: 10.14670/HH-18-146. Epub 2019 Jul 8. PMID: 31282985.
4: Kózka M, Słoczyńska K, Szkaradek N, Waszkielewicz AM, Pękala E, Marona H. Effect of some newly synthesized xanthone and piperazine derivatives with cardiovascular activity on rheology of human erythrocytes in vitro. Clin Hemorheol Microcirc. 2017;67(1):1-14. doi: 10.3233/CH-16001A. PMID: 27567798.
5: Kaur P, Gupta RC, Dey A, Malik T, Pandey DK. Optimization of salicylic acid and chitosan treatment for bitter secoiridoid and xanthone glycosides production in shoot cultures of Swertia paniculata using response surface methodology and artificial neural network. BMC Plant Biol. 2020 May 19;20(1):225. doi: 10.1186/s12870-020-02410-7. PMID: 32429895; PMCID: PMC7238632.
6: Zhang KJ, Gu QL, Yang K, Ming XJ, Wang JX. Anticarcinogenic Effects of α-Mangostin: A Review. Planta Med. 2017 Feb;83(3-04):188-202. doi: 10.1055/s-0042-119651. Epub 2016 Nov 4. PMID: 27824406.
7: Ribeiro J, Veloso C, Fernandes C, Tiritan ME, Pinto MMM. Carboxyxanthones: Bioactive Agents and Molecular Scaffold for Synthesis of Analogues and Derivatives. Molecules. 2019 Jan 5;24(1):180. doi: 10.3390/molecules24010180. PMID: 30621303; PMCID: PMC6337274.
8: Słoczyńska K, Waszkielewicz AM, Marona H. Preliminary assessment of mutagenic and anti-mutagenic potential of some aminoalkanolic derivatives of xanthone by use of the Vibrio harveyi assay. Mutat Res Genet Toxicol Environ Mutagen. 2014 Jul 1;768:8-13. doi: 10.1016/j.mrgentox.2014.02.007. Epub 2014 Apr 24. PMID: 24769486.
9: Ikeya Y, Sugama K, Maruno M. Xanthone C-glycoside and acylated sugar from Polygala tenuifolia. Chem Pharm Bull (Tokyo). 1994 Nov;42(11):2305-8. doi: 10.1248/cpb.42.2305. PMID: 7859329.
10: Daei Farshchi Adli A, Jahanban-Esfahlan R, Seidi K, Samandari-Rad S, Zarghami N. An overview on Vadimezan (DMXAA): The vascular disrupting agent. Chem Biol Drug Des. 2018 May;91(5):996-1006. doi: 10.1111/cbdd.13166. Epub 2018 Jan 24. PMID: 29288534.
